EpSSG RMS 2005.

Rationale: Chemo regimens for high risk rhabdomyosarcoma have become progressively shorter, but more intense. This trial is testing two hypotheses for rhabdo: [1] even more intense upfront chemo +/- doxorubicin and [2] maintenance low-dose chemo (cyclophosphamide/ vinorelbine) versus observation. The second is being reported here. Betting line: If a trial on rhabdo is getting headlines, it’s gotta have some exciting results. Maintenance chemo will improve the primary endpoint of event-free survival at 3 years and the secondary endpoint of overall survival at 5 years. | ASCO Plenary 2018